Physiological-immune resilience risk assessment model for predicting adverse cardiac outcomes in patients with acute myocardial infarction.

Background: Adverse cardiac events have been identified as a major determinant of poor prognosis in patients with acute myocardial infarction (AMI), directly increasing mortality risk. Therefore, this study aimed to establish a physio-immune resilience risk assessment model to identify, at an early stage, the influencing factors of adverse cardiac outcomes in AMI patients, thereby providing clinical guidance for subsequent interventions. Methods: A total of 345 patients diagnosed with AMI between August 2022 and March 2024 were prospectively enrolled. The occurrence of 30-day major adverse cardiac events (MACE) was independently assessed by two cardiology specialists, and participants were categorized into a MACE group and a non-MACE group accordingly. Clinical data and laboratory findings were compared between groups. Least Absolute Shrinkage and Selection Operator (LASSO) regression and multivariate logistic regression were applied to determine the influencing factors of adverse cardiac outcomes. Furthermore, Receiver Operating Characteristic (ROC) curve analysis was performed to evaluate the predictive value of the physio-immune resilience model for MACE in AMI patients. Results: The left ventricular ejection fraction (LVEF) in the MACE group was significantly lower than that in the non-MACE group, whereas high-sensitivity C-reactive protein (hs-CRP) levels were markedly higher ( Conclusion: Patients with AMI undergoing percutaneous coronary intervention (PCI) remain at risk of adverse cardiac outcomes, which may be associated with the physiological resilience score, hs-CRP, SII, and SIRI. These indicators demonstrate substantial predictive value for 30-day MACE in AMI patients. Accordingly, early clinical interventions targeting these risk factors are recommended to reduce the incidence of adverse cardiac outcomes and improve patient prognosis.